The new patent provides 24 claims surrounding Onset’s fundamental Controlled Deployment Technology (CDT) platform.

CDT platform provides minimally invasive and percutaneous access for a wide range of medical procedures including endovascular, coronary, neurovascular and urological applications.

The newly issued patent builds on Onset’s intellectual property foundation, which now includes 4 issued patents and 15 additional pending applications for access systems within the company’s CDT Platform.

Onset CEO Joseph Bishop said this patent solidifies their intellectual property foundation and, along with other issued patents and pending applications, provides them with broad protection for accessing the human body to more effectively complete therapeutic procedures.